Who
Nathan D. Jorgensen
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Voyager Therapeutics; Chief Financial Officer, Vor Biopharma.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $72K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Feb 2021
- Last trade
- 24 Feb 2026
- Last filed
- 26 Feb 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 26 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K4,668 at $3.77 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K4,668 at $3.77 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,250 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,500 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,500 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,250 at $0.00 | filing |
| 3 Oct 2025filed 7 Oct 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K7,666 at $4.78 | filing |
| 21 Feb 2025filed 24 Feb 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 21 Feb 2025filed 24 Feb 2025 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —51,500 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 8 Jul 2024filed 9 Jul 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 6 May 2024filed 7 May 2024 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $1,460834 at $1.75 | filing |
| 1 May 2024filed 3 May 2024 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $1,623917 at $1.77 | filing |
| 1 Mar 2024filed 5 Mar 2024 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $14K6,310 at $2.27 | filing |
| 6 Feb 2024filed 8 Feb 2024 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $2,285985 at $2.32 | filing |
| 29 Jan 2024filed 31 Jan 2024 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 29 Jan 2024filed 31 Jan 2024 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Nov 2023filed 8 Nov 2023 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $1,518834 at $1.82 | filing |
| 1 Sep 2023filed 6 Sep 2023 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $17K6,310 at $2.67 | filing |
| 7 Aug 2023filed 9 Aug 2023 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code F | $2,227834 at $2.67 | filing |
News
No headline names them, or the companies they trade most, lately.